| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.9 |